Likewise, stromal derived VEGF-A was shown to induce VEGFR1-dependent proliferation of primary MM cells, while in vitro inhibition of MM cell lines (i.e., RPMI 8226, U266, ARP1, ARK) by bevacizumab resulted in a reduction of proliferation [92]. The gene discussed is FLT1; the disease is Miyoshi myopathy.